Physician profile
Shanthi Narla
NPI 1114318870
$1,635.57
in general payments reported to CMS, 2019-2025
16 companies · $684 in 2025
The $684 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $192 · 2021: $19.02 · 2022: $244 · 2023: $295 · 2024: $201 · 2025: $684.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,180.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $354.68 | 2022-2025 | |
| Galderma Laboratories, L.P. | $177.00 | 2025 | Nemluvio |
| Abbvie INC. | $165.39 | 2022-2025 | |
| Arcutis Biotherapeutics, INC. | $164.27 | 2023-2024 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $119.82 | 2019-2021 | |
| Incyte Corporation | $104.67 | 2024-2025 | Opzelura |
| Celgene Corporation | $91.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $79.27 | 2025 | |
| Dermavant Sciences, INC. | $69.83 | 2023 | Vtama |
| Pfizer INC. | $68.00 | 2023 | |
| Janssen Scientific Affairs, LLC | $65.50 | 2024-2025 | Tremfya |
| Lilly USA, LLC | $58.74 | 2025 | Taltz |
| Janssen Research & Development, LLC | $52.40 | 2024 | |
| Janssen Biotech, INC. | $34.69 | 2025 | Tremfya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.52 | 2024 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $13.79 | 2023 | Adbry |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shanthi Narla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.